[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"interstitial-cystitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:interstitial-cystitis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,43,77,106,136,160,189,217,236,272,296,317,348,376,403,427,451,487],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100053256","phase-1-venlafaxine-combined-with-education-and-behavioral-intervention-for-bladder-pain-syndrome-100053256",false,"NCT07698626","Venlafaxine Combined With Education and Behavioral Intervention for Bladder Pain Syndrome","A Multicenter, Open-label, Observer-blinded Randomized Controlled Trial Comparing the Efficacy and Safety of Venlafaxine Plus Education and Behavioral Modification Program Versus Education and Behavioral Modification Program Alone in Adults With Interstitial Cystitis\u002FBladder Pain Syndrome","VEN-BPS","Inclusion Criteria:\n\nAge ≥ 18 years (all genders) Confirmed IC\u002FBPS diagnosis fulfilling AUA 2015 and ESSIC standardized diagnostic criteria, ruled out confounding urologic disorders Predominant lower urinary tract symptoms present for most days in the past 3 months Baseline bladder\u002Fpelvic pain and urinary frequency score ≥ 3 points on 0-10 Likert scale within prior 4 weeks\n\nExclusion Criteria:\n\nSymptomatic urethral stricture Active degenerative\u002Finflammatory neurological disease altering bladder\u002Fintestinal function Uncontrolled active autoimmune disease or systemic infection Medical history of pelvic tuberculosis, pelvic radiotherapy or chemotherapy-induced cystitis History of non-cutaneous malignant tumors Current diagnosis of severe psychiatric disorders (major depressive disorder, bipolar disorder, schizophrenia, psychotic disorders) Clinically significant moderate-severe cardiac, pulmonary, hepatic or renal insufficiency Documented hypersensitivity to venlafaxine or other SNRI drugs Concurrent regular use of antibiotics or NSAIDs throughout trial period Pregnancy or breastfeeding state at screening","ALL","18 Years","80 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This study aims to compare two treatment plans for adults with bladder pain syndrome (also called interstitial cystitis), a disease that causes long-lasting bladder pain, frequent urination and urgent need to pee. All participants will receive standardized patient education and behavioral training to relieve urinary discomfort. Half of the participants will only get this behavioral intervention, while the other half will take oral venlafaxine in addition to the same behavioral training for 12 weeks. We will check patients' pain levels, urination frequency, sleep quality, mood and daily life ability at 1, 2, 6 and 12 weeks of treatment. The main goal is to see whether adding venlafaxine can better ease bladder pain and urinary symptoms without obvious side effects. This research will provide safer and more effective treatment suggestions for patients with bladder pain syndrome.",[28,29,30],"Bladder Pain Syndrome","Chronic Pelvic Nociplastic Pain","Interstitial Cystitis","NOT_YET_RECRUITING","2026-07-07",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":22},"2026-12-31",{"date":39,"type":22},"2027-12-31",{"name":41,"class":42},"Beijing Tiantan Hospital","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100095145","genetic-study-of-chronic-prostatitischronic-pelvic-pain-syndrome-cpcpps-100095145","NCT00499317","Genetic Study of Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS)","CP\u002FCPPS","Inclusion Criteria:\n\n* Have symptoms for at least 3 months within the preceding 6 months:\n* Pain in the pelvic area\n* Urinary frequency and\u002For\n* Urinary urgency and\u002For\n* Sexual dysfunction (erectile dysfunction)\n* Have CP\u002FCPPS, Interstitial Cystitis (IC), Bladder Pain Syndrome BPS, or Bladder Fasciculation Syndrome (BFS)\n* Be willing to provide a blood\u002Fsaliva, bladder tissue (from previous biopsy) and urine sample\n* Agree to complete several brief questionnaires\n* Family member of someone with CP\u002FCPPS, BPS, IC or BFS\n* Live in the USA or Canada\n\nExclusion Criteria:\n\n* Major structural\u002Fanatomical urinary tract abnormalities\n* Underlying inborn or congenital conditions which affect the urinary tract\n* Surgery\u002Fchemotherapy in the pelvic area\n* Bacterial cause to CP\u002FCPPS or recurrent Urinary tract infections (UTI)\n* Traumatic cause to CP\u002FCPPS",{"count":51,"type":22},500,"OBSERVATIONAL","Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (CP\u002FCPPS) is a condition with several causes of which some remain unknown. It is believed that some types of CP may be genetic or passed down (inherited) from one generation to the next.\n\nIn this study, we are collecting genetic material and medical information to try to determine if genetic factors play a role in CP\u002FCPPS. We will be collecting DNA (from Blood\u002FSaliva sample) and urine from each participant. Bladder tissue from affected individuals will also be collected. Individuals and families with CP\u002FCPPS will be enrolled. Family members of an individual with CP\u002FCPPS are eligible whether or not they also experience CP\u002FCPPS symptoms.",[55,56,57,58,30],"Chronic Prostatitis (CP)","Chronic Pelvic Pain Syndrome (CPPS)","Painful Bladder Syndrome (PBS)","Benign Frequency Syndrome (BFS)",[60,61,62,63,64,65],"Urgency","Frequency","Pelvic pain","Sexual dysfunction","Erectile dysfunction","Painful intercourse","RECRUITING","2026-06-10",{"date":69,"type":35},"2026-06-11",{"date":71,"type":35},"2007-01-15",{"date":73,"type":22},"2028-12-31",{"name":75,"class":42},"Boston Children's Hospital",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":76},"100523508","phase-2-amniotic-membrane-therapy-for-interstitial-cystitispainful-bladder-syndrome-100523508","NCT06096597","Amniotic Membrane Therapy for Interstitial Cystitis\u002FPainful Bladder Syndrome","Amniotic Membrane Therapy for Interstitial Cystitis\u002FPainful Bladder Syndrome (IC\u002FPBS): a Prospective, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients 18 years of age or older\n* Female\n* English Speaking\n* Diagnosis of IC\u002FPBS\n* Have failed at least one prior treatment for IC\u002FPBS\n\nExclusion Criteria:\n\n* Patients less than 18 years of age\n* Unable to provide consent\n* Non-English speaking\n* Patients with known anatomical malformations of the ureters, bladder, or urethra",true,"FEMALE",{"count":87,"type":22},100,[89,90],"PHASE2","PHASE3","Interstitial cystitis\u002Fpainful bladder syndrome (IC\u002FPBS) is a clinical syndrome in which patients report symptoms of bladder and\u002For pelvic pain with pressure and\u002F or discomfort associated with urinary frequency and urgency.\n\nThe primary objective of this study is to determine the efficacy of amniotic membrane therapy in patients with interstitial cystitis\u002Fpainful bladder syndrome (IC\u002FPBS) as defined by clinically-significant improvement in validated symptom questionnaires.",[30,93,57],"Painful Bladder Syndrome",[95,96],"interstitial cystitis","painful bladder syndrome","2026-06-03",{"date":99,"type":35},"2026-06-05",{"date":101,"type":35},"2024-07-24",{"date":103,"type":22},"2026-06",{"name":105,"class":42},"David Sheyn",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":19,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":76},"100450751","investigation-of-pemf-therapy-for-female-patients-with-icbps-100450751","NCT05149573","Investigation of PEMF Therapy for Female Patients With IC\u002FBPS","Investigation of Non-Invasive Pulsed Electromagnetic Field (PEMF) Therapy for Female Patients With Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)","Inclusion Criteria:\n\n* Previously established clinical diagnosis of IC\u002FPS\n* Current numeric rating scale (NRS) score of ≥ 6\n* History of cystoscopy with hydrodistension with bladder capacity determination under anesthesia\n* No cognitive deficits\n\nExclusion Criteria:\n\n* History of bladder, ovarian, vaginal cancer\n* History of urethral diverticulum\n* History of radiation cystitis\n* History of spinal cord injury or spina bifida\n* History of Parkinson's disease, multiple sclerosis, or stroke\n* Current placement of a pacemaker or metal prosthesis\n* Active urinary tract infection\n* BMI \\> 40\n* Residual urine of \\> 100cc\n* Current pregnant",{"count":114,"type":22},75,[116],"NA","The purpose of this study is to gather information about the safety and effectiveness of the non-pharmacological (non-drug), non-invasive treatment known as low-frequency pulsed electromagnetic field (PEMF) therapy. The study team will distribute the PEMF device to female adults with Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS) to measure its ability to decrease bladder and pelvic pain as well as other urinary symptoms associated with IC\u002FBPS. There are two sequential Aims in this study and subjects will be recruited to participate in only one Aim. In both Aims, data will be collected at baseline\u002Fenrollment, 4-weeks after using PEMF therapy, and 8, 12, and 16 weeks post-enrollment.",[30,119,28],"Chronic Interstitial Cystitis",[95,121,96,122,123,124,125,126],"bladder pain syndrome","painful bladder","bladder pain","urinary urgency","urinary frequency","pulsed electromagnetic field","2026-05-06",{"date":129,"type":35},"2026-05-07",{"date":131,"type":35},"2022-08-29",{"date":133,"type":22},"2027-02",{"name":135,"class":42},"Wake Forest University Health Sciences",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":19,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":76},"100517123","efficacy-of-pulsed-electromagnetic-field-and-heparinbupivacaine-instillations-100517123","NCT06013449","Efficacy of Pulsed Electromagnetic Field and Heparin\u002FBupivacaine Instillations","Investigation of the Effect of Simultaneous Pulsed Electromagnetic Field (PEMF) and Intravesical Heparin - Bupivacaine Cocktail Instillation for the Symptomatic Treatment of Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)","Inclusion Criteria:\n\n* Previously established clinical diagnosis of Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)\n* Current Numeric Rating Scale (NRS) greater than or equal to 5\n* History of cystoscopy with hydrodistension with bladder capacity determination under anesthesia\n* No contraindications to the instillation solution\n* No cognitive deficits\n\nExclusion Criteria:\n\n* History of bladder, ovarian or vaginal cancer\n* History of urethral diverticulum\n* History of radiation cystitis\n* History of spinal cord injury or spina bifida\n* History of Parkinson's Disease\n* History of Multiple Sclerosis (MS)\n* History of Stroke\n* History of genital herpes\n* History of or current cyclophosphamide treatment\n* Current placement of a pacemaker or metal prothesis\n* Active urinary tract infection\n* BMI \\>40\n* Residual urine of \\>100 cc\n* Currently pregnant",{"count":144,"type":22},20,[116],"The objective of this study is to test the idea that Pulsed Electromagnetic Field (PEMF) therapy will serve as a safe therapeutic modality that can effectively be administered simultaneously with bladder instillations of a bupivacaine-heparin cocktail to improve the chronic pain and\u002For associated symptoms of Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS) patients. The study team will distribute the PEMF device to female adults with IC\u002FBPS who have been prescribed bladder instillations of bupivacaine-heparin to see if PEMF therapy in conjunction with bladder instillations of heparin and bupivacaine may be more effective in reducing pain levels and symptomatology of IC\u002FBPS than instillations alone.",[30,119,28],[95,121,122,149,124,125,126,150,151],"chronic pelvic pain","PEMF","bladder instillation","2026-03-30",{"date":154,"type":35},"2026-03-31",{"date":156,"type":22},"2026-09",{"date":158,"type":22},"2027-12",{"name":135,"class":42},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":188},"100449064","eppic-easing-pelvic-pain-interventions-clinical-research-program-100449064","NCT05127616","EPPIC: Easing Pelvic Pain Interventions Clinical Research Program","A Brief, Transdiagnostic Cognitive Behavioral Treatment for Urological Chronic Pelvic Pain Syndrome: Processes, Predictions, Outcomes","EPPIC","Inclusion Criteria:\n\n* Ages 18-70 years (inclusive)\n* Male or female\n* All genders, races, ethnic groups\n* MD-confirmed diagnosis of IC\u002FBPS or CP\u002FCPPS by study urologist or urogynecologist\n* Pelvic pain including uncomfortable sensations of pressure or discomfort that are not described as outright pain) of at least six months duration\n* Pelvic pain intensity of at least moderate severity (defined as 3 or greater on a 0-10 Numerical Rating Scale and causes life interference weekly and limit(s) participant's life or work-related activities, general activity level, and\u002For enjoyment of life) over the past 3 months.\n* Ability to understand and provide informed consent\n* Either not taking medications or if taking medications willing to refrain from starting new medications until after the initial 2-week pre-treatment baseline period ends unless medically necessary.\n* A minimum 6th grade reading level based on the Wide Range Achievement Test (WRAT 4)\n* Willing to be randomized to either CBT or Support\u002FEducation and to follow the protocol to which s\u002Fhe has been assigned\n* Willing to be contacted for follow up assessments at week 12 and 3, 6 months after treatment ends\n* Willing to attend sessions\n* Able to maintain symptom diaries and complete paper work\n* Access to telephone and computer or smartphone\n* Willing and able to provide adequate information for locator purposes\n\nExclusion Criteria: Urologic-Specific\n\n* Presence of a neurological condition (e.g., MS, Parkinson's disease, paraplegia) affecting the bladder\n* The presence of a symptomatic urethral stricture (males only)\n* History of cystitis caused by tuberculosis or radiation or chemotherapies\n* Participant has been diagnosed and treated for a pelvic-related malignancy (colon, bladder, prostate, ovarian, endometrial, uterine, testicular, penile, cervical, vaginal, or rectal cancer)\n\nExclusion Criteria: General\n\n* Participant has a medical condition(s) whose nature or severity (unstable, life threatening, etc.) would influence adversely the conduct of the clinical trial, confound interpretation of study results, and\u002For compromise volunteer safety and engagement with study demands.\n* Gross cognitive impairment, deafness, blindness, vision problems (severe), hearing problems (severe)\n* Has a major psychiatric disorder which would impede conduct of the clinical study. These clinical disorders would include but are not limited to major depression with a high risk of suicidal behavior (i.e. intent or plan), current or recent (within the past 3 months) history of alcohol or substance abuse\u002Fdependence, a lifetime history of schizophrenia or schizoaffective disorder; or organic mental disorder\n* Current involvement in psychotherapy directed specifically toward relief of urological symptoms\n* Schedule does not permit participation in clinic sessions or home practice including plans to move out of the area, lack of reliable transportation, etc.\n* Characteristics related to inability to complete the study protocol\n* Unable to read or fluently speak English\n* Inability to complete screening visits\n* Inaccessible for interventions and\u002For follow up evaluations","70 Years",{"count":170,"type":22},240,[116],"The EPPIC (Easing Pelvic Pain Interventions Clinical Research Program) study evaluates an ultra-brief, 4 session cognitive behavioral pain treatment transdiagnostic in design for urologic chronic pain syndrome (UCPPS) with clinical and practical advantages over existing behavioral therapies whose length and focus limits their adoption by clinicians and coverage for mechanistically similar comorbidities. A theoretically informed, practical, empirically grounded approach will systematically unpack CBT's working mechanisms, clarify for whom it works, ease dissemination, appeal to patients, providers, payers, and policy makers in the COVID-19 era favoring low resource intensity treatments, and reduce cost and inefficiencies associated with high intensity therapies whose complexity, length, and scarcity restricts uptake and impact.",[174,30,28,175,176,177,178],"Urologic Chronic Pelvic Pain Syndrome (UCPPS)","Chronic Prostatitis","Chronic Pain","Chronic Pelvic Pain Syndrome","Chronic Overlapping Pain Disorders","2026-01-22",{"date":181,"type":35},"2026-01-26",{"date":183,"type":35},"2022-08-10",{"date":185,"type":22},"2028-07-31",{"name":187,"class":42},"State University of New York at Buffalo",3,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":213,"locationsCount":216},"100546430","phase-2-safety-efficacy-and-frequency-of-administration-of-vnx001-in-the-treatment-of-interstitial-cystitis--bladder-pain-syndrome-icbps-100546430","NCT06394830","Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis \u002F Bladder Pain Syndrome (IC\u002FBPS)","A Phase 2b, Open Label, Single-Arm, Multi-Center, Multiple Dose, 14-Day Study to Evaluate the Safety, Efficacy, and Frequency of Intravesical Administration of VNX001 in Acute Treatment of Subjects With Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS) Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity","Inclusion Criteria:\n\n1. Enrolled and completed Study VNX001-111 (i.e., at any site that is concurrently conducting the VNX001-111 study, a subject must have previously enrolled and completed Study VNX001-111 to be eligible for entry into the VNX001-110 study) and meet all other inclusion\u002Fexclusion criteria.\n2. Be able and willing to give a signed informed consent and to follow study instructions.\n3. Be male or female, ≥ 18 years of age.\n4. Have a history of IC\u002FBPS for at least 9 months prior to the study, either treated (e.g. Elmiron®, RIMSO-50®), or untreated.\n5. Have received a cystoscopy in association with their diagnosis of IC\u002FBPS within 1 year of screening.\n6. Have a score of ≥ 14 and ≤ 30 on the PUF questionnaire, completed at screening.\n7. Have an episode of acute bladder pain of moderate to severe intensity with a minimum score of 4 on the 11-point bladder pain NRS at time of screening and 15 minutes post void immediately prior to study drug administration.\n\nExclusion Criteria:\n\n1. For females, have a positive pregnancy test at screening or be pregnant or lactating.\n\n   Note: Females considered to be of child-bearing potential must commit to using a consistent and medically acceptable method of birth control for the duration of the study: hormonal (i.e., oral, transdermal patch, implant, or injection) on a stable dose for at least 3 months prior to screening; double barrier (i.e., condom with spermicide or diaphragm with spermicide) consistently for at least 2 weeks prior to screening; and intrauterine device for at least 3 months prior to screening; or only have a partner who has been vasectomized for at least 6 months prior to screening or exclusively has same-sex partners. Female participants who are abstinent from heterosexual intercourse as part of their usual lifestyle will also be eligible for participation. Females considered to be of non-childbearing potential include: At least 1 year postmenopausal; surgically sterile (tubal ligation, bilateral oophorectomy, salpingectomy, of hysterectomy); congenitally sterile; diagnosed as infertile and not undergoing treatment to reverse infertility.\n2. Males who are sexually active with females and are not willing to commit to an acceptable method of birth control for the duration of the study.\n3. Postmenopausal women who, if taking hormone replacement therapy, have not been stabilized on a regimen of hormone replacement therapy within 3 months of screening.\n4. Have a known hypersensitivity to heparin or lidocaine.\n5. Have used any local anesthetic by any route (other than intravesical instillation) within 48-hours prior to study drug administration, or used a lidocaine patch or lidocaine containing topical compounds within 14 days prior to study drug administration.\n6. Have used a tricyclic antidepressant, or a gamma-aminobutyric acid (GABA) analogue (gabapentin or pregabalin), unless taking a stable dose of the medication for ≥ 3 weeks. The stable dose of gabapentin may not exceed 1,200 mg per day, and the stable dose of pregabalin may not exceed 150 mg per day.\n7. Have used prohibited drugs as determined by self-report, positive urine drug screen, or in the opinion of the investigator be under the influence of drugs affecting mentation precluding their ability to follow the study protocol or bias study results.\n8. Have a known abnormal laboratory test value that, in the investigator's judgement, is clinically significant.\n9. Have a neurogenic bladder or other disorder that, in the opinion of the investigator, may cause neurogenic bladder (including Parkinson's disease, multiple sclerosis, epilepsy, myasthenia gravis, movement disorders, spinal cord damage).\n10. Have pain or a pain disorder that, in the opinion of the investigator, would make it difficult to discriminate pelvic pain of bladder origin from the other pain.\n11. Have any of the following central nervous system (CNS) conditions that in the opinion of the investigator would impact the subject's study participation due to their ability to follow the study protocol or bias study results, severe diagnosed: major depressive disorder, bipolar disorder, schizophrenia, general anxiety disorder, attention deficit disorder, obsessive compulsive disorder, or other major CNS disorder.\n12. Have history of arrhythmias, conduction disturbances, or cardiac disease, or any coexisting medical condition that, in the opinion of the investigator, may be significant or interfere with study procedures or interpretation of study results.\n13. Had bladder instillation therapy within 14 days prior to study entry.\n14. Had an in-office cystoscopy within 7 days prior to study drug administration.\n15. Had dilatation (hydrodistension) of bladder within 3 months of study entry.\n16. Evidence or suspected presence of cancer detected during cystoscopy.\n17. Has received any investigational drug or device within 30 days prior to screening.\n18. Is currently enrolled in another investigational drug or device study.\n19. Is unwilling or unable to abide by the requirements of the study.\n20. Have an actively bleeding lesion or area in the bladder as detected by dipstick urinalysis and investigator assessment, immediately prior to randomization (Section 9.5.1.6). If the investigator determines that active bleeding is not occurring and that it is safe for the subject, the subject may continue in the study.\n21. Have a history of coagulopathy or taking anticoagulants.\n22. Are taking any of the following medications:\n\n    * Phenytoin\n    * Carbamazepine\n    * St. John's Wort\n    * Phenobarbital\n    * Rifampin\n23. Have had any of the following:\n\n    * Bacterial cystitis within 30 days as demonstrated by a positive urine culture (≥ 105 bacteria per mL)\n    * History of pelvic irradiation or radiation cystitis\n    * History or presence of uterine, cervical, pelvic, rectal, ovarian, or vaginal cancer\n    * History of benign or malignant bladder tumors\n    * Current chemotherapy\n    * History or presence of tuberculous cystitis\n    * History or presence of chemical cystitis, including that due to cyclophosphamide\n    * History or presence of urinary schistosomiasis\n    * Bladder or ureteral calculi\n    * Clinically significant infectious vaginitis\n    * Currently uncontrolled genital herpes\n    * History or presence of urethral diverticulum\n    * Presence of bladder fistulae\n    * History of ketamine use",{"count":197,"type":22},50,[89],"This is an open-label study that will enroll participants with Interstitial Cystitis \u002F Bladder Pain Syndrome (IC\u002FBPS).\n\nThe study will assess PRN (as needed) dosing of up to 6 intravesical (via catheter) doses of VNX001 (study drug) to treat acute instances of moderate to severe bladder pain over a 14-day period. The main aim of the study is to tally the number of doses and assess pain before and after doses. The study will review the safety and tolerability of VNX001.\n\nParticipants will need to attend up to seven (7) clinic visits (1 for screening and up to 6 visits for VNX001 dosing) or at least one (1) clinic visit (for a combined screening\u002Fdosing visit) and 5 telephone visits over the course of 14 days. Participants will also be asked complete a diary or telephone call each day of the study, in order to record bladder pain, urinary urgency, side effects, and medications taken.",[30,28],[202,203,204,205,206,207],"interstitial cystitis (IC)","bladder pain syndrome (BPS)","alkalinized lidocaine","heparin","intravesical","VNX001","2026-01-21",{"date":179,"type":35},{"date":211,"type":35},"2024-12-13",{"date":103,"type":22},{"name":214,"class":215},"Vaneltix Pharma, Inc.","INDUSTRY",5,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":23,"phases":226,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":235},"100495893","phase-2-safety-and-efficacy-study-of-vnx001-compared-to-its-individual-components-lidocaine-and-heparin-or-placebo-in-subjects-with-icbps-100495893","NCT05737121","Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC\u002FBPS","A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, and the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis\u002FBladder Pain Syndrome Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity; The Engage 2024 Study","Inclusion Criteria:\n\n* Be able and willing to give a signed informed consent and to follow study instructions\n* Be male or female, ≥ 18 years of age\n* Have a history of IC\u002FBPS for at least 9 months prior to the study\n* Have a score of ≥ 16 and ≤ 30 on the Pelvic Pain and Urgency\u002FFrequency (PUF) questionnaire, completed at screening\n* Have an episode of acute bladder pain of moderate to severe intensity with a minimum score of 5 on the 11-point bladder pain NRS at time of screening and 15 minutes post void immediately prior to study drug administration.\n* Have previously received a therapeutic intravesicular anesthetic treatment according to medication history\n\nExclusion Criteria:\n\n* For females, have a positive pregnancy test at screening or be pregnant or lactating\n* Males who are sexually active with females and are not willing to commit to an acceptable method of birth control for the duration of the\n* Postmenopausal women who, if taking hormone replacement therapy, have not been stabilized on a regimen of hormone replacement therapy within 3 months of screening\n* Have a known hypersensitivity to heparin or lidocaine\n* Have used any local anesthetic by any route within 48-hours prior to study drug administration, or used a lidocaine patch or lidocaine containing topical compounds within 14 days prior to study drug administration\n* Have used a tricyclic antidepressant, or a gamma-aminobutyric acid (GABA) analogue (gabapentin or pregabalin), unless taking a stable dose of the medication for ≥ 3 weeks. The stable dose of gabapentin may not exceed 1,200 mg per day, and the stable dose of pregabalin may not exceed 150 mg per day\n* Have used any pain medication within 6 hours prior to study drug administration\n* Have used narcotics or medical marijuana ≤ 3 weeks prior to study entry\n* Have used prohibited drugs as determined by self-report, positive urine drug screen, or in the opinion of the investigator be under the influence of drugs affecting mentation precluding their ability to follow the study protocol or bias study results\n* Have a known abnormal laboratory test value that, in the investigator's judgement, is clinically significant.\n* Have a neurogenic bladder or other disorder that, in the opinion of the investigator, may cause neurogenic bladder (including Parkinson's disease, multiple sclerosis, epilepsy, myasthenia gravis, movement disorders, spinal cord damage)\n* Have pain or a pain disorder that, in the opinion of the investigator, would make it difficult to discriminate pelvic pain of bladder origin from the other pain\n* Have any of the following central nervous system (CNS) conditions that in the opinion of the investigator would impact the subject's study participation due to their ability to follow the study protocol or bias study results, severe diagnosed: major depressive disorder, bipolar disorder, schizophrenia, general anxiety disorder, attention deficit disorder, obsessive compulsive disorder, or other major central nervous system disorder\n* Have history of arrhythmias, conduction disturbances, or cardiac disease, or any coexisting medical condition that, in the opinion of the investigator, may be significant or interfere with study procedures or interpretation of study results\n* Had anesthetic bladder instillation therapy within 14 days prior to study entry\n* Had an in-office cystoscopy within 7 days of study drug administration\n* Had dilatation (hydrodistension) of bladder within 3 months of study entry\n* Evidence or suspected presence of cancer detected during cystoscopy 7 days prior to or at time of initial screening\n* Has received any investigational drug or device within 30 days prior to screening\n* Is currently enrolled in another investigational drug or device study\n* Is unwilling or unable to abide by the requirements of the study\n* Have an actively bleeding lesion or area in the bladder as detected by dipstick urinalysis and investigator assessment, immediately prior to randomization\n* Have a history of coagulopathy or taking anticoagulants.\n* Are taking any of the following medications, which are inducers of CYP1A2 and\u002For CYP3A4: Phenytoin, Carbamazepine, St. John's Wort, Phenobarbital, Rifampin\n* Have had any of the following:\n\n  * Bacterial cystitis within 30 days as demonstrated by a positive urine culture (≥ 105 bacteria per mL)\n  * History of pelvic irradiation or radiation cystitis\n  * History or presence of uterine, cervical, pelvic, rectal, ovarian, or vaginal cancer\n  * History of benign or malignant bladder tumors\n  * Current chemotherapy\n  * History or presence of tuberculous cystitis\n  * History or presence of chemical cystitis, including that due to cyclophosphamide\n  * History or presence of urinary schistosomiasis\n  * Bladder or ureteral calculi\n  * Clinically significant infectious vaginitis\n  * Currently uncontrolled genital herpes\n  * History or presence of urethral diverticulum\n  * Presence of bladder fistulae\n  * History of ketamine use",{"count":225,"type":22},120,[89],"This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HCl)) for the reduction of bladder pain in patients with interstitial cystitis (IC) \u002F bladder pain syndrome (BPS), Who Have an Episode of Acute Bladder Pain of Moderate to Severe Intensity.",[30,28],[202,203,204,205,206,207],{"date":179,"type":35},{"date":232,"type":35},"2023-05-22",{"date":103,"type":22},{"name":214,"class":215},14,{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":254,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":76},"100539118","pain-type-and-interstitial-cystitisbladder-pain-syndrome-treatment-100539118","NCT06299683","Pain Type and Interstitial Cystitis\u002FBladder Pain Syndrome Treatment","Mechanistic-Based Treatment of Interstitial Cystitis\u002FBladder Pain Syndrome","Inclusion Criteria:\n\n* 18 years of age or older;\n* Diagnosis of IC\u002FBPS as indicated by structured assessments;\n* Capable of giving written informed consent;\n* Able to enroll for the duration of the study period;\n\nExclusion Criteria:\n\n* Comorbid neurological conditions including spinal cord injury or systematic neurologic illnesses, or central nervous system diseases such as brain tumor or stroke;\n* Current or history of diagnosis of primary psychotic or major thought disorder within the past five years;\n* Hospitalization for psychiatric reasons other than suicidal ideation, homicidal ideation, and\u002For PTSD (within the past 5 years);\n* Psychiatric or behavioral conditions in which symptoms are unstable or severe (e.g. current delirium, mania, psychosis, active suicidal ideation, homicidal ideation, substance abuse dependency) reported within the past six months;\n* Non-English speaking;\n* Presenting symptoms at time of screening that would interfere with participation, specifically active suicidal ideation with intent to harm oneself or active delusional or psychotic thinking;\n* Difficulties or limitations communicating over the telephone or via teleconferencing systems;\n* Any planned life events that would interfere with participating in the key elements of the study;\n* Any major active medical issues that could preclude participation;\n* Currently pregnant;\n* Currently being treated for cancer;\n* Cancer-related pain;\n* Recently or actively participating in treatment similar to those being investigated (e.g. individual psychotherapy or pelvic floor pt).",{"count":244,"type":22},220,[116],"Interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS) is a severe pain condition affecting 3-8 million people in the United States lacking treatments that work. Emotional suffering is common in IC\u002FBPS and known to make physical symptoms worse, and studies show patient sub-groups respond differently to treatment. Individuals with IC\u002FBPS have distinct subgroups, or \"phenotypes,\" largely characterized by the distribution of pain throughout the body. Supported by our preliminary evidence, the overall goal of this project is to assess how IC\u002FBPS phenotype may affect response to two different therapies often given without regard to patient phenotype, pelvic floor physical therapy (PT) and cognitive-behavioral therapy (CBT) for IC\u002FBPS.",[119,28,93,248,249,30,250,251,252,175,253],"Cystitis, Interstitial","Cystitis, Chronic Interstitial","Interstitial Cystitis, Chronic","Interstitial Cystitis (Chronic) With Hematuria","Interstitial Cystitis (Chronic) Without Hematuria","Chronic Prostatitis With Chronic Pelvic Pain Syndrome",[95,121,255,256,257,258,259,260,261,262,263],"clinical trial","psychosocial intervention","pelvic pain","therapy","urological chronic pelvic pain syndrome","chronic prostatitis","self-management","cognitive behavioral therapy","pelvic floor physical therapy","2026-01-20",{"date":208,"type":35},{"date":267,"type":35},"2024-05-01",{"date":269,"type":22},"2028-04-04",{"name":271,"class":42},"Vanderbilt University Medical Center",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":23,"phases":282,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":76},"100544237","acupuncture-first-for-icbps-100544237","NCT06366269","Acupuncture First for IC\u002FBPS","Acupuncture as First-line Therapy for Patients With Interstitial Cystitis\u002FPainful Bladder Syndrome","Inclusion Criteria:\n\n* Meets American Urologic Association (AUA) criteria for interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS): \"An unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than 6 weeks duration, in the absence of other identifiable cause\"\n* Negative urine culture\n* Has completed cystoscopic evaluation for IC\u002FBPS\n\nExclusion Criteria:\n\n* History of recurrent urinary tract infection (2 or more culture-positive in 6 months or 3 or more in 12 months)\n* History of overactive bladder\n* History of bleeding disorder or are currently on chronic anti-coagulation\n* Post-void residual \\>100mL\n* Has previously undergone any of the following treatments for any indication: acupuncture, pelvic floor physical therapy, pre-tibial nerve stimulation (PTNS), sacral neuromodulation, or intradetrusor Botox\n* Prior bladder augmentation\n* Currently undergoing or will undergo treatment for a urologic or gynecologic malignancy\n* Currently pregnant (if applicable, based on self-report)\n* Implanted pacemaker or defibrillator (AICD) or any metallic implants below umbilicus (eg hip or knee replacements)\n* Non-English speaking and reading","89 Years",{"count":281,"type":22},34,[116],"The goal of this clinical trial is to learn if acupuncture in addition to behavioral changes can better treat in women with bladder pain syndrome (also known as interstitial cystitis) that have not received other treatments. The main question it aims to answer is:\n\nDoes acupuncture improve pain symptoms on the Interstitial Cystitis Index? Researchers will compare six (6) weeks behavioral management alone to behavioral management and acupuncture.\n\nParticipants will\n\n* complete surveys about their bladder pain symptoms\n* make behavioral changes that have been shown to improve bladder pain symptoms\n* attend six (6) weekly acupuncture sessions\n* attend six (6) weekly physical therapy sessions after finishing acupuncture",[28,30],[286,121,95],"acupuncture","2026-01-06",{"date":289,"type":35},"2026-01-08",{"date":291,"type":35},"2025-01-21",{"date":293,"type":22},"2026-10",{"name":295,"class":42},"University Hospitals Cleveland Medical Center",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":303,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":306,"conditions":307,"keywords":308,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":76},"100086864","identifying-genetic-causes-of-icbps-100086864","NCT00389142","Identifying Genetic Causes of IC\u002FBPS","Genetic Studies in Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS)","Inclusion Criteria:\n\n* Diagnosis of IC\u002FBPS\n* Males and females of any age\n* Urinary frequency - more than 1X\u002Fhour, and\u002For\n* Dysuria, and\u002For\n* Pelvic, suprapubic, or abdominal pain - for 3 months or longer\n* Nocturia\n* Normal urinary stream (by history)\n* No evidence of active bacterial UTI (no pyuria \\& negative urinary culture for last 3 months)\n* First degree relative of someone with above symptoms\n\nExclusion Criteria:\n\n* Major structural\u002Fanatomical urinary tract abnormalities by ultrasound\n* Underlying inborn conditions affecting the urinary tract\n* Surgery\u002Fchemotherapy affected pelvic area\n* GI or GU cancers\n* Severe Constipation in children only","1 Year",{"count":305,"type":22},1000,"Interstitial cystitis (IC), also called Bladder Pain syndrome (BPS) is a common condition with no known cause or cure. Twin studies and family accounts have suggested that the condition may be genetic or passed down (inherited) from one generation to another.\n\nIn this study, the investigators are collecting genetic material via blood or saliva and medical information from families in North America in an attempt to identify genetic factors that may cause IC\u002FBPS. The investigators are enrolling inviduals with IC\u002FBPS and their family members (family members with and without IC like symptoms). Travel to Boston not required.",[30,28],[257,125,122,124],"2025-12-09",{"date":311,"type":35},"2025-12-16",{"date":313,"type":35},"2006-01-15",{"date":315,"type":22},"2030-12-31",{"name":75,"class":42},{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":327,"briefSummary":328,"conditions":329,"keywords":335,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":345,"locationsCount":347},"100495100","phase-3-the-role-of-preoperative-immunonutrition-on-morbidity-and-immune-response-after-cystectomy-incyst-trial-100495100","NCT05726786","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)","The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy - A Multicenter Randomized Controlled Trial (INCyst Trial)","INCyst","Inclusion Criteria:\n\n* Patient undergoing open cystectomy (for all reasons)\n* Age ≥18 years\n* Ability and willingness to provide informed consent documented by signature\n\nExclusion Criteria:\n\n* Contraindications to IN, e.g. known hypersensitivity or allergy to lactose, fish oil or soy lecithin\n* Severe diarrhoea requiring medical attention\n* Current treatment with any immunosuppressive drug\n* In standard practice, pregnant or lactating women are systematically rejected by the surgeon for this surgical procedure. Furthermore, during the pre-surgical anaesthesia consultation, the eligibility of each patient for anaesthesia will be assessed according to the usual criteria and recommendations of the anaesthesia service of the CHUV\n* Other clinically significant concomitant disease affecting immunity (e.g., severe renal failure, HIV, SLE, transplant recipient, ...)\n* Inability to follow the procedures of the study, e.g. due psychological disorders, dementia, etc.\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Use of IN independently of the study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* Emergency procedure (less than 7 days between screening and surgery)",{"count":326,"type":22},232,[90],"The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy.\n\nAs a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN.\n\nThis is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.",[330,30,93,331,332,333,334],"Bladder Cancer","Neurogenic Bladder","Hemorrhagic Cystitis","Endometriosis","Bladder Disease",[336,337,338,339],"Cystectomy","Immunonutrition","Complication","Malnutrition","2025-12-02",{"date":309,"type":35},{"date":343,"type":35},"2023-04-10",{"date":293,"type":22},{"name":346,"class":42},"Centre Hospitalier Universitaire Vaudois",4,{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":76},"100418852","early-phase-1-safety-and-efficacy-of-aloe-vera-in-the-management-of-the-symptoms-of-interstitial-cystitis-100418852","NCT04734106","Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis","A Double-Blind, Placebo-Controlled Study to Establish the Safety and Efficacy of Super-Concentrated, Freeze-Dried Aloe Vera in the Management of the Symptoms of Interstitial Cystitis","Inclusion Criteria:\n\n* Females or males, aged 18 years or older\n* Females of childbearing potential must agree to use acceptable methods of birth control. Acceptable methods are oral and injectable preparations, double barrier, vasectomized partner, or abstinence.\n* Participant must sign and date the informed consent.\n* Participant must report a urinary frequency of at least 11 times per 24-hour day, on average over the previous four weeks.\n* Participant must report a pain\u002Fdiscomfort score of 4 or greater on a 0-9 Likert scale.\n* These reported urinary symptoms of frequency and pain\u002Fdiscomfort must have been present for at least the previous 24 weeks prior to the first baseline screening visit.\n* Participants must report in the baseline voiding diary at least one voided volume greater than or equal to 75cc in a 24-hour period.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to aloe vera in any form as reported by the participant or derived from medical records.\n* History of Bladder tumors (malignant or benign).\n* Current active bladder or urethral calculus.\n* History of urethral cancer within the previous five years.\n* Any disease which, in the opinion of the investigator, may be unstable or have bearing on the outcome of the study, including severe debilitating concurrent medical conditions such as coronary artery disease, azotemia, moderate to severe hepatic insufficiency, etc.\n* Previous treatment with Cytoxan (cyclophosphamide).\n* History of cyclophosphamide or chemical cystitis or tuberculosis or radiation cystitis.\n* History of pelvic radiation treatment, bladder cancer or cancer in situ, or urethral cancer.\n* History of any other neoplastic process currently requiring systemic, nonprophylactic treatment.\n* History of urethral diverticulum.\n* Inability to void spontaneously.\n* Subjects with interstitial cystitis symptoms alleviated by current therapy regimen.\n* Uncontrolled diabetes mellitus.\n* Previous enrollment in an aloe vera study.\n* Previous use of Desert Harvest super-concentrated, freeze-dried aloe vera capsules.\n* Any imminent change in residence that could compromise compliance.\n* Unlikely to be compliant due to unmanaged medical or psychological problem, including dementia, aphasia, or other deficits of cognition or speech\u002Flanguage function that will interfere with the participant's ability to complete the study.\n* Substance abuse or dependency problem within the past two years for which patient received no treatment.\n\nMale-Specific Exclusion Criteria:\n\n* Males with a history of prostate cancer within the previous five years.\n* Males with a prostatic infection within the previous three months.\n\nFemale-Specific Exclusion Criteria:\n\n* Females with a history of uterine, cervical, or vaginal cancer within the previous five years.\n* Pregnant or lactating females.",{"count":356,"type":22},30,[358],"EARLY_PHASE1","The purpose of this study is to assess the safety and efficacy of super-concentrated, freeze-dried aloe vera capsules for treatment of interstitial cystitis.",[30,119,28],[362,28,363,364,365,366,367],"Interstitial Cystitis (IC)","Urinary urgency","Urinary frequency","Bladder pain","Nocturia","Urinary incontinence","2025-08-26",{"date":370,"type":35},"2025-08-27",{"date":372,"type":35},"2025-02-18",{"date":374,"type":22},"2027-07",{"name":135,"class":42},{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":383,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":386,"briefSummary":387,"conditions":388,"keywords":391,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":76},"100444090","early-phase-1-a-novel-medical-system-for-quantitative-diagnosis-and-personalized-precision-botulinum-neurotoxin-injection-in-chronic-pelvic-pain-management-100444090","NCT05062902","A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management","An Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management","Inclusion Criteria:\n\n* Inclusion criteria for interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS) patients will be:\n\n  1. Woman aged 18 to 60.\n  2. Have a clinical diagnosis of IC\u002FBPS.\n  3. Pain, pressure, or discomfort in the bladder and\u002For pelvic area for the past 6 months or more, associated with lower urinary tract symptoms (such as frequency of urination), in the absence of other explanation of the symptoms (e.g., urinary tract infection).\n  4. Myofascial pain diagnosed with palpable contracted muscle fibers.\n  5. Pelvic muscle tenderness by assessment of pelvic floor muscles on digital pelvic examination.\n  6. Pelvic floor hypertonicity (PFH), measured using vaginal manometry (pressure \\> 35 cm∙H2O).\n  7. Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Exclusion criteria consist of the following:\n\n  1. History of pelvic malignancy and sexually transmitted diseases.\n  2. Bleeding disorder such as coagulopathy\n  3. History of neurological disorders, such as spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis or myasthenia gravis.\n  4. Pregnancy, breast feeding or desiring for pregnancy in the coming year.\n  5. Subjects with history of pelvic surgery (e.g., pain from mid-urethral sling or pelvic mesh),\n  6. Pelvic malignancy (urinary tract, gynecologic, gastrointestinal)\n  7. Active fistula\n  8. Radiation cystitis\n  9. Cyclophosphamide cystitis\n  10. Pre-existing anorectal disorders\n  11. Infections near the injection sites\n  12. History of drug or alcohol abuse\n  13. Hypersensitivity to BoNT\n  14. Steroids or hormone usage will be carefully considered by the research team for inclusion.\n\nParticipants with on-going BoNT therapies will not be screened until the complete drug washout is confirmed.","60 Years",{"count":385,"type":22},46,[358],"The purpose of this study is to evaluate if it is possible to use intravaginal high-density surface electromyography to guide Botulinum neurotoxin (BoNT) injection to treat pelvic floor muscle overactivity that complicates Chronic Pelvic Pain (CPP).",[30,176,389,390],"Pelvic Floor; Relaxation","Pelvic Floor Disorders",[392,149,393],"hypertonicity","electromyography","2025-08-14",{"date":396,"type":35},"2025-08-19",{"date":398,"type":22},"2025-09-15",{"date":400,"type":22},"2027-12-01",{"name":402,"class":215},"HillMed Inc.",{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":407,"acronym":4,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":409,"enrollmentInfo":410,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":76},"100582431","intravesical-ozone-therapy-for-interstitial-cystitisbladder-pain-syndrome-100582431","NCT06863220","Intravesical Ozone Therapy for Interstitial Cystitis\u002FBladder Pain Syndrome","Inclusion Criteria:\n\n* Age 18-65 years\n* Histopathologically or clinically confirmed IC (per AUA guidelines)\n* Symptoms for at least 6 months\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* Active urinary tract infection\n* Bladder malignancy\n* Pregnancy or breastfeeding\n* Known ozone allergy\n* Intravesical therapy within 3 months\n* G6PD deficiency","65 Years",{"count":411,"type":22},60,[116],"This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of intravesical ozone therapy in 60 patients with interstitial cystitis (IC). Participants were assigned to ozone therapy, placebo, or standard care groups for 3 weeks, with follow-up at 6 weeks. The primary outcome was the change in O'Leary-Sant ICSI score. Secondary outcomes included VAS pain score, SF-36 physical health, and urinary frequency.",[30,28],[30,121,416,417],"ozone therapy","intravesical ozone","2025-04-23",{"date":420,"type":35},"2025-04-27",{"date":422,"type":22},"2025-06-01",{"date":424,"type":22},"2026-06-01",{"name":426,"class":42},"Medipol University",{"id":428,"slug":429,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":23,"phases":435,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":76},"100450614","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-stem-cells-for-peyronies-disease-ed-and-interstitial-cystitis-100450614","NCT05147779","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis","Inclusion Criteria:\n\n* Diagnosis of Peyronie's Disease, erectile dysfunction, or Interstitial Cystitis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur",{"count":144,"type":22},[25],"This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis",[438,439,30],"Erectile Dysfunction","Peyronie's Disease",[438,439,441,30],"stem cell treatment","2025-04-15",{"date":444,"type":35},"2025-04-17",{"date":446,"type":35},"2021-09-12",{"date":448,"type":22},"2025-12",{"name":450,"class":42},"The Foundation for Orthopaedics and Regenerative Medicine",{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":459,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":461,"conditions":462,"keywords":467,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":483,"locationsCount":486},"100571359","evaluating-the-efficacy-and-patient-experience-of-catheter-free-intravesical-instillation-100571359","NCT06719232","Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation","Evaluating the Efficacy and Patient Experience of Catheter-Free Intravesical Instillation: a Prospective Observational Study","NOCATIN","Inclusion Criteria:\n\n* Male and female patients aged between 18 and 80 years.\n* Patients for whom the treating physician has determined that intravesical instillation is necessary due to one of the following conditions:\n* Interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS).\n* Recurrent urinary tract infections (UTIs).\n* Non-muscle invasive bladder cancer.\n* Post-radiation cystitis.\n* Post-chemotherapy cystitis.\n* Negative urine culture within the last two weeks.\n* Patients who provide verbal and written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Urinary tract infection within the past month or currently active infection.\n* Diagnosed bleeding disorders or recurrent macroscopic hematuria.\n* Post-void residual urine volume greater than 100 ml.\n* Mental condition that prevents reliable cooperation.",{"count":460,"type":22},300,"This study aims to evaluate a catheter-free method for delivering medications directly into the bladder, known as intravesical instillation, which is commonly used to treat conditions such as interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS), recurrent urinary tract infections, bladder cancer, and post-chemotherapy or post-radiation cystitis.\n\nThe study investigates whether this method, which eliminates the need for catheterization, reduces discomfort and complications while maintaining treatment effectiveness. By collecting data on patient experiences and outcomes, the study seeks to determine if this approach provides a safer and more comfortable alternative to traditional catheter-based treatments.",[30,463,464,330,334,465,28,466],"Recurrent Cystitis","Haemorrhagic Cystitis","Intravesical Instillation","Recurrent Urinary Tract Infections",[468,469,470,471,472,473,474,475,476],"intravesical therapy","catheterization","recurrent urinary tract infection","IC\u002FBPS","Interstitial Cystitis\u002FBladder Pain syndrome","Post-chemotherapy Cystitis","Post-Irradiation Cystitis","Intravesical instillation","UroDapter","2024-12-07",{"date":479,"type":35},"2024-12-12",{"date":481,"type":35},"2024-10-01",{"date":448,"type":22},{"name":484,"class":485},"Jahn Ferenc South Pest Teaching Hospital","OTHER_GOV",2,{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":84,"sex":85,"minAge":18,"maxAge":409,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":76},"100427377","phase-1-peppermint-oil-for-the-treatment-of-interstitial-cystitis--bladder-pain-syndrome-100427377","NCT04845217","Peppermint Oil for the Treatment of Interstitial Cystitis \u002F Bladder Pain Syndrome","Efficacy of Peppermint Oil in a Randomized, Single-Blind, Placebo Controlled Trial in Women With Interstitial Cystitis\u002FBladder Pain Syndrome","Inclusion Criteria:\n\n* Women ages 18-65 years old\n* Diagnosed with IC\u002FBPS for at least one month prior to study enrollment\n\nExclusion Criteria:\n\n* Culture proven urinary tract infection within 1 month of randomization\n* Gross hematuria\n* Currently pregnant or breastfeeding\n* Unable to speak and read English\n* History of allergic reaction to peppermint, coconut or enteric coating\n* History of malabsorption syndrome\n* History of gastroparesis\n* History of gastric bypass surgery\n* History of gastrointestinal, genitourinary or pelvic cancer in the last 5 years\n* History of insulin dependent diabetes\n* History of active urinary stone disease",{"count":87,"type":22},[25,89],"The purpose of this study is to assess the use of peppermint oil as a treatment for Interstitial Cystitis\u002FBladder Pain Syndrome (IC\u002FBPS).",[30],[95,121,499],"peppermint","2022-08-19",{"date":502,"type":35},"2022-08-22",{"date":504,"type":35},"2021-09-15",{"date":506,"type":22},"2023-12",{"name":508,"class":42},"University of Louisville"]